# EDGAR Filing Document

**Accession Number:** 0000846475
**File Stem:** 0001104659-26-006240
**Filing Date:** 2026-1
**Character Count:** 15717
**Document Hash:** 6f362011412a24110aa28c7f30e21151
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-006240.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001104659-26-006240

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260122

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZYNEX INC
- **CENTRAL INDEX KEY:** 0000846475
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 870403828
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38804
- **FILM NUMBER:** 26556463

**BUSINESS ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** (800)-495-6670

**MAIL ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS INC
- **DATE OF NAME CHANGE:** 20050812

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS   INC
- **DATE OF NAME CHANGE:** 20040120

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FOX RIVER HOLDINGS  INC
- **DATE OF NAME CHANGE:** 20031126

?xml version='1.0' encoding='ASCII'? ZYNEX, INC._January 22, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

 **OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): January 22, 2026**

**ZYNEX, INC.**

 **(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Nevada**<br>**(State or other jurisdiction**<br>**of incorporation)** | **001-38804**<br>**(Commission File Number)** | **90-0275169**<br>**(IRS EmployerIdentification No.)** |
| **9655 Maroon Circle, Englewood, CO**<br>**(Address of principal executive offices)** | **9655 Maroon Circle, Englewood, CO**<br>**(Address of principal executive offices)** | **80112**<br>**(Zip Code)** |

---

**Registrant's telephone number, including area code: (800) 495-6670**

**Not Applicable**

 **(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.001 par value per share | ZYXI | The Nasdaq Stock Market LLC\* |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\*On December 17, 2025, Zynex, Inc. (the "Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that Nasdaq had determined to delist the Company's common stock as a result of the Company and certain of its subsidiaries commencing voluntary cases under chapter 11 of title 11 of the United States Code on December 15, 2025. On December 24, 2025, the Company's common stock was suspended from trading on Nasdaq and began trading on the Pink Limited Market, operated by OTC Markets Group, under the symbol "ZYXIQ." The delisting of the Company's common stock from Nasdaq will become effective 10 calendar days after Nasdaq has filed a Form 25 with the U.S. Securities and Exchange Commission (the "SEC"). The deregistration of the Company's common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended, will be effective 90 days, or such shorter period as the SEC may determine, after the filing of the Form 25.

------

**Item 5.02.** **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 22, 2026, the Board of Directors of the Company (the "Board") of Zynex, Inc. (the "Company") determined to (i) remove Thomas Sandgaard from all positions he holds with the Company and its subsidiaries, including as Chair and member of the Board, and Chair and member of the Technology Committee of the Board, effective immediately, and (ii) terminate and cancel all unvested equity awards previously granted to Mr. Sandgaard in connection with such positions, and (iii) terminate all existing cash compensation arrangements with Mr. Sandgaard.

On January 21, 2026, Mr. Sandgaard was indicted by a federal grand jury for alleged health care and securities fraud related offenses. Following inquiry into and consideration of the accusations and factual claims in the documents charging Mr. Sandgaard, the Board has determined that Mr. Sandgaard has violated the Company's Code of Business Conduct and Ethics (the "Code of Ethics") and that it is advisable and in the best interests of the Company and its stockholders to remove Mr. Sandgaard from all positions he holds with the Company.

Mr. Sandgaard has been furnished with a copy of this Current Report on Form 8-K and will be given an opportunity to respond. Any response received from Mr. Sandgaard will be filed as an amendment hereto.

In connection with the removal of Mr. Sandgaard, on January 22, 2026, the Board appointed Steven Dyson, the Company's Chief Executive Officer and current member of the Board, to serve as Chair of the Board, effective immediately.

In addition, on January 22, 2026, the Board approved a decrease in the number of directors constituting the full Board from seven to six directors in accordance with the Company's Articles of Incorporation and Bylaws, effective immediately.

**Item 7.01.** **Regulation FD Disclosure.**

On January 22, 2026, the Company issued a press release announcing the removal of Mr. Sandgaard from the Board and the Company's response to related events. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K (as to Exhibits 99.1), is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information contained in Item 7.01 (as to Exhibit 99.1) of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document or filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Cautionary Note Regarding the Chapter 11 Cases**

The Company cautions that trading in the Company's securities during the pendency of the Chapter 11 Cases (as defined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on December 16, 2025) is highly speculative and poses substantial risks. Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by the holders of the Company's securities in the Chapter 11 Cases. The Company expects that its equity holders will experience a significant loss on their investment if the Restructuring Transactions are implemented.

**Forward-Looking Statements**

This Current Report on Form 8-K includes "forward-looking statements," within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including, in particular, any statements about our plans, strategies, objectives, initiatives, roadmap and prospects. We generally use the words "may," "will," "could," "expect," "anticipate," "believe," "estimate," "plan," "intend," "aim" and similar expressions in this Current Report on Form 8-K to identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements, include, but are not limited to, statements related to the Restructuring

Transactions described above, including the Company's ability to complete the Restructuring Transactions on the terms contemplated by the RSA, on the timeline contemplated or at all, and the Company's ability to realize the intended benefits of the Restructuring Transactions. The Company's actual results may differ materially from those anticipated in these forward-looking statements as a result of certain risks and other factors. Some of these risks and uncertainties include: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to the Company's ability to obtain Court approval with respect to motions in the Chapter 11 Cases and approval of requisite stakeholders and confirmation by the Court of the Plan, the effects of the Chapter 11 Cases on the Company and its various constituents, the impact of Court rulings in the Chapter 11 Cases, the ultimate outcome of the Chapter 11 Cases in general, the length of time the Company will operate under the Chapter 11 Cases, attendant risks associated with restrictions on the Company's ability to pursue its business strategies while the Chapter 11 Cases are pending, risks associated with third-party motions in the Chapter 11 Cases, the potential adverse effects of the Chapter 11 Cases on the Company's liquidity, the likelihood of the cancellation of the Company's common stock in the Chapter 11 Cases, uncertainty regarding the Company's ability to retain key personnel and management, uncertainty and continuing risks associated with the Company's ability to achieve its goals and continue as a going concern. Such risks and other factors also include those listed in Part II, Item 1A. "Risk Factors" and in Part I, Item 1A. "Risk Factors" in our 2024 Form 10-K/A filed with the SEC on July 24, 2025, Part II, Item 1A. "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed with the SEC on July 31, 2025, Part II, Item 1A. "Risk Factors" of the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the SEC on November 17, 2025, and our other filings with the SEC. When considering these forward-looking statements, you should keep in mind the cautionary statements in this report and the documents incorporated by reference. New risks and uncertainties arise from time to time, and we cannot predict those events or how they may affect us. We assume no obligation to update any forward-looking statements after the date of this report as a result of new information, future events or developments, except as required by applicable laws and regulations.

You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those identified herein, could cause our results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, we do not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of the filing of this Current Report on Form 8-K or to reflect the occurrence of unanticipated events or otherwise.

**Item 9.01.** **Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [Press Release, dated January 22, 2026](zyxi-20260122xex99d1.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| DATED: January 23, 2026 | **ZYNEX, INC.** | **ZYNEX, INC.** |
|  | By: | */s/ John Bibb* |
|  | Name: | John Bibb |
|  | Title: | Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](zyxi-20260122xex99d1002.jpg)

**New Zynex Leadership Responds to Indictment of Former Executives**

**ENGLEWOOD, Colo., Jan. 22, 2026 —** Zynex, Inc. (ZYXIQ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today issued the following statement regarding the federal indictments of two former executives.

"Zynex, Inc. is aware of the federal indictments of two former executives," said John Bibb, Chief Legal Officer.

The individuals named in the indictment are no longer employed by Zynex and play no role in Zynex's current operations. Following the indictment, the Board of Directors removed Thomas Sandgaard as director and Chair of the Board. The company has not been charged in any criminal or civil enforcement matters.

"Over the last six months, Zynex has executed a complete overhaul of its leadership, compliance program, billing practices, and operational controls," Bibb added. "Under entirely new leadership, we have delivered on our commitment to the highest integrity in our business practices and implemented rigorous compliance oversight."

Zynex has cooperated extensively with the Department of Justice and other regulators and continues to seek a long-term resolution of ongoing investigations while the company is currently reorganizing under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division.

Bibb concluded, "As we create a new future for Zynex, we are committed to building trust through transparency, integrity, and compliance while we fulfill our mission to improve the quality of life for patients suffering from debilitating pain and other conditions."

**About Zynex, Inc.**

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation. For additional information, please visit: www.zynex.com.

**Investor Relations Contact:**<br>Vikram Bajaj, CFO<br>ir@zynex.com

**Media Contact:**

Britt Logan DiGiulio

Email: media@zynex.com

------

9655 Maroon Circle, Englewood, CO 80112 \| Zynex.com

------